Výsledky vyhledávání

Akademický článek

Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer.

Autor: Wagle MC; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. zineb.mounir@mail.mcgill.ca mariewagle@gmail.com., Castillo J; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Srinivasan S; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Holcomb T; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Yuen KC; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Kadel EE; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Mariathasan S; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Halligan DL; Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom., Carr AR; Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom., Bylesjo M; Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom., McAdam PR; Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom., Lynagh S; Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom., Marien KM; HistoGeneX, Antwerp, Belgium., Kockx M; HistoGeneX, Antwerp, Belgium., Waumans Y; HistoGeneX, Antwerp, Belgium., Huang SA; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Lackner MR; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California., Mounir Z; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. zineb.mounir@mail.mcgill.ca mariewagle@gmail.com.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2020 Jul; Vol. 8 (7), pp. 844-850. Date of Electronic Publication: 2020 Apr 22.

Zobrazit plný text záznamu

Akademický článek

Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level.

Autor: Lu S; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California; Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California., Chang CJ; Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California., Guan Y; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California., Szafer-Glusman E; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California., Punnoose E; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California., Do A; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California., Suttmann B; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California., Gagnon R; Division of Expression Analysis Genomics, Q2 Solutions, Morrisville, North Carolina., Rodriguez A; Department of Translational Research, Epic Sciences Inc., San Diego, California., Landers M; Department of Translational Research, Epic Sciences Inc., San Diego, California., Spoerke J; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California., Lackner MR; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California., Xiao W; Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California. Electronic address: wzxiao@stanford.edu., Wang Y; Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, California. Electronic address: wang.yulei@gene.com.

Publikováno v: The Journal of molecular diagnostics : JMD [J Mol Diagn] 2020 Jun; Vol. 22 (6), pp. 770-781. Date of Electronic Publication: 2020 Apr 02.

Zobrazit plný text záznamu

Akademický článek

Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.

Autor: Moore HM; Oncology Biomarker Development, Genentech Inc., South San Francisco, California., Savage HM; Oncology Biomarker Development, Genentech Inc., South San Francisco, California., O'Brien C; IDEAYA Biosciences, South San Francisco, California., Zhou W; Translational Oncology, Genentech Inc., South San Francisco, California., Sokol ES; Cancer Genomics Research, Foundation Medicine Inc., Cambridge, Massachusetts., Goldberg ME; Cancer Genomics Research, Foundation Medicine Inc., Cambridge, Massachusetts., Metcalfe C; Translational Oncology, Genentech Inc., South San Francisco, California., Friedman LS; ORIC Pharmaceuticals, South San Francisco, California., Lackner MR; IDEAYA Biosciences, South San Francisco, California., Wilson TR; Oncology Biomarker Development, Genentech Inc., South San Francisco, California. wilson.timothy@gene.com.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2020 Jan; Vol. 19 (1), pp. 292-303. Date of Electronic Publication: 2019 Sep 18.

Zobrazit plný text záznamu

Akademický článek

CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.

Autor: Castillo J; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Wu E; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Lowe C; Department of Bioanalytical Sciences, Development Sciences, Genentech, Inc., South San Francisco, California., Srinivasan S; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., McCord R; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Wagle MC; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Jayakar S; Department of Research Pathology, Genentech, Inc., South San Francisco, California., Edick MG; Department of Research Pathology, Genentech, Inc., South San Francisco, California., Eastham-Anderson J; Department of Research Pathology, Genentech, Inc., South San Francisco, California., Liu B; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Hutchinson KE; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Jones W; Q Solutions-EA Genomics, Morrisville, North Carolina., Stokes MP; Cell Signaling Technology, Inc., Danvers, Massachusetts., Tarighat SS; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Holcomb T; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Glibicky A; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Romero FA; Department of Discovery Chemistry, Genentech, Inc., South San Francisco, California., Magnuson S; Department of Discovery Chemistry, Genentech, Inc., South San Francisco, California., Huang SA; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Plaks V; Department of Bioanalytical Sciences, Development Sciences, Genentech, Inc., South San Francisco, California., Giltnane JM; Department of Research Pathology, Genentech, Inc., South San Francisco, California., Lackner MR; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California., Mounir Z; Department of Oncology Biomarker Development, Development Sciences, Genentech, Inc., South San Francisco, California. zineb.mounir@mail.mcgill.ca.

Publikováno v: Cancer research [Cancer Res] 2019 Aug 01; Vol. 79 (15), pp. 3916-3927. Date of Electronic Publication: 2019 Jun 10.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání